Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1456 participants.

Also called NCT06347133

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,456 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06347133
  • EudraCT 2023-509302-30
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Bulgaria, Canada, Czechia, France, Germany, Hungary, Italy, Poland, Slovakia, South Africa, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06347133. Randomized; quadruple masking; primary purpose treatment. Start 2024-05-21 (actual); primary completion 2026-06-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
Acronym
MUIR-3
Condition
Hypertriglyceridemia
Intervention (Drug)
Plozasiran Injection
Intervention (Drug)
Placebo
Lead sponsor
Arrowhead Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06347133
Content hash
f17970da6a08e21d2382884caccac98971cf3c6db95a1e10e32b5694d9f2945b